Cargando…
Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
Metastatic prostate cancer continues to kill approximately 30,000 men per year. Since 2010, five new therapeutic agents have been Food and Drug Administration (FDA) approved to treat metastatic castration-resistant prostate cancer (mCRPC). With the increasing number of therapies available to clinici...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814966/ https://www.ncbi.nlm.nih.gov/pubmed/25865849 http://dx.doi.org/10.4103/1008-682X.150843 |